WO2014134457A3 - Conjugates comprising cell-binding agents and cytotoxic agents - Google Patents

Conjugates comprising cell-binding agents and cytotoxic agents Download PDF

Info

Publication number
WO2014134457A3
WO2014134457A3 PCT/US2014/019434 US2014019434W WO2014134457A3 WO 2014134457 A3 WO2014134457 A3 WO 2014134457A3 US 2014019434 W US2014019434 W US 2014019434W WO 2014134457 A3 WO2014134457 A3 WO 2014134457A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
agents
cell
cytotoxic
binding
Prior art date
Application number
PCT/US2014/019434
Other languages
French (fr)
Other versions
WO2014134457A2 (en
Inventor
Wayne C. Widdison
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of WO2014134457A2 publication Critical patent/WO2014134457A2/en
Publication of WO2014134457A3 publication Critical patent/WO2014134457A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates

Abstract

The invention provides linker compounds and cytotoxic compounds that are useful for forming a CBA-drug conjugate and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
PCT/US2014/019434 2013-02-28 2014-02-28 Conjugates comprising cell-binding agents and cytotoxic agents WO2014134457A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361770796P 2013-02-28 2013-02-28
US61/770,796 2013-02-28

Publications (2)

Publication Number Publication Date
WO2014134457A2 WO2014134457A2 (en) 2014-09-04
WO2014134457A3 true WO2014134457A3 (en) 2014-12-04

Family

ID=50288321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/019434 WO2014134457A2 (en) 2013-02-28 2014-02-28 Conjugates comprising cell-binding agents and cytotoxic agents

Country Status (1)

Country Link
WO (1) WO2014134457A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562059B2 (en) * 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CN112826940A (en) * 2014-11-11 2021-05-25 杭州多禧生物科技有限公司 Conjugates of cytotoxic molecules and cell-binding receptor molecules
JP6802840B2 (en) 2015-06-09 2020-12-23 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド Antibody-drug conjugates, intermediates, methods for their production, pharmaceutical compositions and applications
EP3313845B1 (en) 2015-06-29 2020-08-12 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
US10287256B2 (en) 2016-11-23 2019-05-14 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
SG11201907050PA (en) 2017-02-28 2019-09-27 Univ Kinki Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
US20220072144A1 (en) 2018-09-20 2022-03-10 Daiichi Sankyo Company, Limited Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
JPWO2022014698A1 (en) 2020-07-17 2022-01-20

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134977A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
WO2012061590A1 (en) * 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012135517A2 (en) * 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2012138749A1 (en) * 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134977A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
WO2012061590A1 (en) * 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012135517A2 (en) * 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2012138749A1 (en) * 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAU A ET AL: "CONJUGATION OF DOXORUBICIN TO MONOCLONAL ANTI-CARCINOEMBRYONIC ANTIGEN ANTIBODY VIA NOVEL THIOL-DIRECTED CROSS-LINKING REAGENTS", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 3, no. 10, 1 January 1995 (1995-01-01), pages 1299 - 1304, XP001193824, ISSN: 0968-0896, DOI: 10.1016/0968-0896(95)00125-Z *

Also Published As

Publication number Publication date
WO2014134457A2 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
PH12019502018A1 (en) Compositions, formulations and methods for treating ocular diseases
WO2014194030A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
PH12016501411B1 (en) Bifunctional cytotoxic agents
NZ752526A (en) Pyrrolobenzodiazepine conjugates
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2021010550A (en) Hydrophilic antibody-drug conjugates.
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
NZ710729A (en) Amatoxin derivatives
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016013999A (en) Antibody-drug-conjugate and its use for the treatment of cancer.
MX2017013167A (en) Site-specific antibody-drug conjugates.
MY174813A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2014134486A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
EP3501548A4 (en) Tissue factor-targeted antibody-drug conjugate
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
WO2014163714A3 (en) Antibody drug conjugates
EP3271401A4 (en) Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
MX2016013704A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
MX2017003476A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same.
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
EP3710039A4 (en) Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710741

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14710741

Country of ref document: EP

Kind code of ref document: A2